<DOC>
	<DOCNO>NCT00685841</DOCNO>
	<brief_summary>A 12 week study investigate safety effectiveness arformoterol give twice daily compare placebo subject COPD .</brief_summary>
	<brief_title>A Pivotal Study Safety Effectiveness Arformoterol Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This study double-blind , double-dummy , randomize , placebo- active-controlled , multicenter , parallel-group study adult subject primary clinical diagnosis COPD . Approximately 800 subject randomize study . Study participation consist total eight ( 8 ) study visit approximately four ( 4 ) month subject . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion Criteria Subject may male female must age less equal 35 year day inform consent sign . Female subject great equal 65 year age must serum pregnancy test conduct Visit 1 confirm negative prior randomization . Subjects childbearing potential must use acceptable method birth control . Female subject consider childbearing potential must : document surgically sterile ( defined status posthysterectomy bilateral tubal ligation ) OR postmenopausal Subject must primary diagnosis COPD , may include component chronic bronchitis and/or emphysema . Diagnosis make screen process . Subject must minimum smoke history 15 packyears ( packyears = number cigarette pack per day time number year ) . Subject must chest xray consistent diagnosis COPD ( e.g. , diagnostic pneumonia , infection , atelectasis , pneumothorax active/ongoing pulmonary condition ) take less equal 3 month prior study start . If chest xray take less equal 3 month prior study start , recent result unavailable review , chest xray perform . Subject must able complete study questionnaire log reliably . Exclusion Criteria Female subject pregnant lactating . Subject participate investigational drug study within 30 day prior study start , currently participate another investigational drug study . Subject whose schedule travel prevents completion require visit . Subject schedule inpatient hospitalization , include elective surgery ( patient outpatient ) trial . Subject lifethreatening/unstable respiratory status , include upper low respiratory tract infection , within previous 30 day prior study start . Subject known history asthma chronic respiratory disease ( include current history sleep apnea ) COPD ( chronic bronchitis and/or emphysema ) . Subject history cancer except nonmelanomatous skin cancer . Subjects history cancer consider surgically cure without recurrence within past 10 year may participate study . History hematologic/lymphatic malignancy treat chemotherapy radiation allow . Subject history lung resection one full lobe . Subject require continuous supplemental oxygen therapy ( unless subject resides elevation great equal 4,000 foot ) . Subject change dose type medication COPD within 14 day prior screen visit . Subject know sensitivity ( R , R ) formoterol , ipratropium , salmeterol albuterol excipients contain formulation . Subject history substance abuse drug abuse within 12 month study start , positive urine drug screen study start . Subject use prescription drug concomitant betaagonist administration contraindicate ( e.g. , betablockers ) .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
</DOC>